<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143336" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Malignant Orbital Tumors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kajal</surname>
            <given-names>Smile</given-names>
          </name>
          <aff>University College of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cui</surname>
            <given-names>David</given-names>
          </name>
          <aff>Sinai Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winters</surname>
            <given-names>Ryan</given-names>
          </name>
          <aff>Ochsner Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Smile Kajal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Cui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Winters declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143336.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The orbits are paired structures separated by the nasal cavity and ethmoidal sinuses, which protect and house the globe and contain extraocular muscles, nerves, blood vessels, lacrimal apparatus, and adipose tissues. The walls of each orbit are formed by parts of&#x000a0;7 bones: frontal, sphenoid, maxillary, zygomatic, palatine, ethmoid, and lacrimal.<xref ref-type="bibr" rid="article-143336.r1">[1]</xref>&#x000a0;Tumors arising in orbit can be classified according to their cell of origin as either primary, secondary, or metastatic.</p>
        <p>Primary orbital tumors arise from structures within the confines of the bony orbit, including vascular, neural, mesenchymal, and osseous, and those arising from the lacrimal gland. Secondary orbital tumors are lesions that, by contiguity, extend to involve the orbit from neighboring structures such as the paranasal sinus, conjunctiva, eye (globe), eyelid, lacrimal sac, anterior and middle cranial fossae,&#x000a0;other facial&#x000a0;bone, skull, nasopharynx, palate, and parotid gland. The orbit can also rarely be the site for metastasis for some distant tumors.<xref ref-type="bibr" rid="article-143336.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-143336.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>All anatomic structures of the orbit can give rise to malignancy. The malignant tumors of the orbit can be classified according to the site of origin and histology as follows:&#x000a0;<xref ref-type="bibr" rid="article-143336.r3">[3]</xref><xref ref-type="bibr" rid="article-143336.r4">[4]</xref><xref ref-type="bibr" rid="article-143336.r5">[5]</xref>&#x000a0;</p>
        <p>
<bold>Primary Tumors</bold>
</p>
        <p>
<bold>Lymphoproliferative</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ocular adnexal lymphomas: These are the most common adult malignant orbital tumors and are&#x000a0;primarily seen in&#x000a0;older patients with a female predominance. They can originate from the conjunctiva, eyelids, lacrimal glands, and orbital soft tissue. These are most commonly mucosal-associated, low-grade B-cell lymphomas (MALT lymphomas).<xref ref-type="bibr" rid="article-143336.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Lacrimal gland</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lacrimal gland neoplasms are often differentiated into&#x000a0;2 distinct categories, epithelial and nonepithelial, with nonepithelial tumors accounting for 50% to 60% of masses. Other rare tumors include mesenchymal tumors.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lacrimal gland lymphomas account for the majority of malignant nonepithelial gland tumors. Other tumors of nonepithelial lymphatic origin include extranodal marginal zone lymphomas, follicular lymphomas, and diffuse large B-cell lymphomas.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>Malignant epithelial gland tumors&#x000a0;include adenocarcinomas, adenoid cystic carcinomas, mucoepidermoid carcinomas, pleomorphic adenocarcinomas, epithelial-myoepithelial carcinomas, acinar cell carcinomas, transitional cell carcinomas, and melanomas.</p>
          </list-item>
          <list-item>
            <p>Mesenchymal tumors are rare and constitute only 10% to 15% of all lacrimal gland tumors. Examples include sarcomas, malignant peripheral nerve sheath tumors, and malignant rhabdoid tumors.</p>
          </list-item>
        </list>
        <p><bold>Mesenchymal:&#x000a0;</bold>These are usually aggressive tumors seen in both pediatric and adult populations and are named according to their cell of origin. These tumors include rhabdomyosarcomas (the most common pediatric malignant orbital tumor),&#x000a0;liposarcomas, myxofibrosarcomas, leiomyosarcomas, osteosarcomas, and chondrosarcomas.<xref ref-type="bibr" rid="article-143336.r7">[7]</xref></p>
        <p><bold>Vasculogenic:&#x000a0;</bold>These are rare tumors of the orbit and&#x000a0;include hemangiopericytomas, angiosarcomas, and epitheloid hemangioendotheliomas. Hemangiopericytomas constitute around 1% of all orbital tumors. The cell of origin is the pericytes of the vascular wall or pluripotent perivascular cells. Patients typically present in the fifth decade of life with no gender predilection.</p>
        <p><bold>Intraocular:&#x000a0;</bold>These include tumors originating from ocular epithelium, such as retinoblastomas and orbital melanomas. Retinoblastomas are the most frequent intraocular malignancy in children, occurring before the age of 5 and with no gender predilection. Primary orbital melanomas constitute the most common primary intraocular malignancy in adults. They arise from the uveal tract, which consists of the choroid (the most common site of origin), ciliary body, and iris.</p>
        <p><bold>Germ cell:&#x000a0;</bold>These tumors are of embryonic cell origin and are extremely rare malignant tumors of the orbit. Examples include teratomas, yolk sac tumors, and granulocytic sarcomas.</p>
        <p><bold>Secondary Tumors:&#x000a0;</bold>Based on the site of origin, these tumors can be classified as follows:</p>
        <p>
<bold>From sinonasal malignancies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Frontoethmoidal malignancies (like squamous cell carcinomas [SCC] and adenocarcinomas), maxillary sinus malignancies, ethmoid sinus malignancies, and rarely sphenoid sinus malignancies</p>
          </list-item>
          <list-item>
            <p>Nasopharyngeal carcinomas</p>
          </list-item>
          <list-item>
            <p>Sinonasal undifferentiated carcinomas (SNUC)</p>
          </list-item>
          <list-item>
            <p>NK/T-cell lymphomas</p>
          </list-item>
        </list>
        <p>
<bold>From the central nervous system</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Endocranial tumors of the skull base, like esthesioneuroblastomas</p>
          </list-item>
          <list-item>
            <p>Malignant meningiomas</p>
          </list-item>
        </list>
        <p>
<bold>From the globe, conjunctiva, or nasolacrimal duct</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Squamous cell carcinomas, basal cell carcinomas (BCC), adenocarcinomas, oncocytic carcinomas, mucoepidermoid carcinomas, adenoid cystic carcinomas, melanomas, Merkel cell tumors, sebaceous carcinomas</p>
          </list-item>
        </list>
        <p>
<bold>From the skin&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Squamous cell carcinomas</p>
          </list-item>
          <list-item>
            <p>Basal cell carcinomas</p>
          </list-item>
          <list-item>
            <p>Melanomas</p>
          </list-item>
          <list-item>
            <p>Adnexal structure carcinomas (Merkel cell, apocrine, etc)</p>
          </list-item>
        </list>
        <p><bold>Metastatic Tumors:&#x000a0;</bold>The orbit can be the site of metastasis (1% to 3% of all orbital tumors), and the most common types include metastases from the breast, prostate, melanoma, and lungs.<xref ref-type="bibr" rid="article-143336.r8">[8]</xref></p>
      </sec>
      <sec id="article-143336.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Primary orbital malignancies account for 82%&#x000a0;to 87% of all orbital masses, secondary orbital malignancies represent 9%&#x000a0;to 11%, and orbital metastasis accounts for 4%&#x000a0;to 8% of overall orbital masses.<xref ref-type="bibr" rid="article-143336.r5">[5]</xref>&#x000a0;Out of all tumors of the orbit, 68% are benign, and 32% are malignant.<xref ref-type="bibr" rid="article-143336.r9">[9]</xref>&#x000a0;In adults older than 60 years of age, lymphoproliferative lesions are the most common primary orbital tumor, with orbital adnexal lymphomas accounting for 67% to 90% of orbital lymphoproliferative tumors and 24% to 30% of all space-occupying orbital tumors.<xref ref-type="bibr" rid="article-143336.r2">[2]</xref><xref ref-type="bibr" rid="article-143336.r10">[10]</xref>&#x000a0;</p>
        <p>Metastases from other cancers constitute 1% to 3% of orbital tumors. Metastatic breast cancer is the most common, accounting for 48% to 53% of orbital metastases, followed by metastatic prostate carcinoma, melanoma, and lung cancer.<xref ref-type="bibr" rid="article-143336.r11">[11]</xref> In children, neuroblastomas, Ewing sarcoma, Wilms tumor, and leukemias are the more common metastatic orbital lesions, while rhabdomyosarcoma is the most common primary malignancy.</p>
      </sec>
      <sec id="article-143336.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Non-Hodgkin lymphomas, specifically the mucosa-associated lymphoid tissue (MALT) subtype of low-grade B-cell lymphoma, are the most common orbital lymphomas. Other histological subtypes include follicular lymphomas, diffuse large B-cell lymphomas, and mantle-cell lymphomas.</p>
        <p>Various molecular and immunohistochemistry techniques can determine the oncogenes responsible for orbital tumors. For instance, <italic toggle="yes">BRAF</italic> mutation in orbital melanoma can be used to identify the cutaneous (metastatic) versus uveal (local) origin, and <italic toggle="yes">MYCN</italic> oncogene in neuroblastoma is indicative of aggressive behavior and high metastatic potential of the tumor. <italic toggle="yes">RAS</italic> and <italic toggle="yes">MET</italic> mutations are seen in epithelial lacrimal gland tumors, and the <italic toggle="yes">Rb</italic> gene is implicated in retinoblastoma.<xref ref-type="bibr" rid="article-143336.r5">[5]</xref><xref ref-type="bibr" rid="article-143336.r11">[11]</xref><xref ref-type="bibr" rid="article-143336.r12">[12]</xref></p>
      </sec>
      <sec id="article-143336.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>A tissue biopsy is necessary to make a pathological diagnosis. The characteristic histopathological features of some of the orbital tumors include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Orbital lymphomas</bold>: These tumors originate most commonly from B-cells. The histology shows atypical lymphocytic cells with nuclear membrane abnormalities.&#x000a0;Immunologic markers are particularly valuable for precise diagnosis.<xref ref-type="bibr" rid="article-143336.r11">[11]</xref><xref ref-type="bibr" rid="article-143336.r13">[13]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Adenocystic carcinomas</bold> of the lacrimal gland: Tumors appear nonencapsulated and consist of generally bland-appearing epithelial cells arranged in nests or chords, thus forming a characteristic cribriform or Swiss cheese&#x02013;like pattern.<xref ref-type="bibr" rid="article-143336.r11">[11]</xref><xref ref-type="bibr" rid="article-143336.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Hemangiopericytomas: </bold>These tumors appear histologically as dense, hypercellular tumors with spindle-shaped cells. The tumors are vascular with a variably dilated, vascular branching pattern classically described as staghorn vessels.<xref ref-type="bibr" rid="article-143336.r11">[11]</xref><xref ref-type="bibr" rid="article-143336.r13">[13]</xref>&#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Malignant nerve sheath tumors</bold>: The lesions are sarcomas and often lack a single tissue of origin at histologic analysis. However, the pathology can show spindle-cell neoplasms with necrotic foci, atypical mitoses, and the absence of differentiated cells that are S-100 positive on immunohistochemistry.<xref ref-type="bibr" rid="article-143336.r11">[11]</xref><xref ref-type="bibr" rid="article-143336.r13">[13]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Squamous cell carcinomas</bold>: Nests of squamous cells with variable differentiation that may form keratin pearls. Intracellular bridges may be present.<xref ref-type="bibr" rid="article-143336.r14">[14]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Basal cell carcinomas</bold>: Basophilic cells that may display peripheral pallisading of the nuclei. The most common growth pattern is nodular, with pushing borders of aggregates of basal cells. Infiltrative growth pattern displays tendrils of cells extending deeply.<xref ref-type="bibr" rid="article-143336.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143336.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The history focuses on orbital, ocular, and neurologic systems, but performing a complete initial history and physical examination is always important. Masses of the orbit are often slowly growing, and patients may&#x000a0;report dull, aching eye pain, retro-orbital headache, or visual complaints like unilateral decreased vision or diplopia before any proptosis, exophthalmos, or vertical dystopia becomes evident clinically.&#x000a0;A mnemonic known as&#x000a0;'the 6 Ps' (pain, progression, proptosis, pulsation, palpation, and periocular changes) has been developed to help focus a history and physical examination&#x000a0;while ensuring completeness in evaluating for underlying orbital pathology.<xref ref-type="bibr" rid="article-143336.r16">[16]</xref>&#x000a0;Family history is often less relevant, as most orbital tumors are not germ-line mutations (some notable exceptions being retinoblastoma and neurofibromatosis).<xref ref-type="bibr" rid="article-143336.r17">[17]</xref>&#x000a0;Social history is most important to elucidate occupational exposures that may predispose to certain tumors (ie, sun exposure for cutaneous/eyelid SCC and BCC).</p>
        <p>Physical examination will similarly focus on ocular, orbital, and neurologic symptoms but must also encompass the sinonasal cavities and neck if a malignant mass is suspected. Lesions in the intraconal space classically cause slow axial proptosis with compressive optic neuropathy,&#x000a0;while lesions in the extraconal space are more likely to arise from periorbital structures such as the paranasal sinuses, skin, sensory nerves, or lacrimal gland tumors.<xref ref-type="bibr" rid="article-143336.r18">[18]</xref>&#x000a0;Symptoms such as unilateral nasal obstruction, epiphora, and recurrent unilateral epistaxis, in addition to ocular symptoms, may point towards orbital tumors secondary to sinonasal malignancy.</p>
        <p>A complete ophthalmic examination, including visual acuity, pupillary response, extraocular muscle function, exophthalmometry, tonometry, and fundoscopy, is required. Skin, conjunctival, and corneal sensation, along with any lid lag, should also be documented. Findings such as tortuous conjunctival vessels or choroidal-retinal folds may point towards orbital pathology.&#x000a0;For the measurement of ptosis, the margin-to-reflex distance, which is the distance in millimeters between the corneal light reflex to the upper eyelid (MRD1) or lower eyelid (MRD2), can be used to measure eyelid positioning, ptosis, lagophthalmos, ectropion, and scleral show. A complete cranial nerve examination is required, with special attention paid to V1, V2, V3, and any pain with ocular movements. Unilateral proptosis points more towards primary or secondary orbital pathology rather than a systemic disease like Graves ophthalmopathy. Asymmetry of &#x0003e;2 mm between the prominence of the&#x000a0;2 eyes is considered significant. Palpation may reveal a firm globe with restricted mobility, which is worrisome for orbital malignancy.<xref ref-type="bibr" rid="article-143336.r19">[19]</xref><xref ref-type="bibr" rid="article-143336.r5">[5]</xref><xref ref-type="bibr" rid="article-143336.r20">[20]</xref></p>
        <p>Intranasal examination is warranted in cases of proptosis or suspicion of intraorbital mass and should include anterior rhinoscopy and nasal endoscopy. A thorough neck examination should also be undertaken to include the parotid glands and cervical lymph nodes.</p>
      </sec>
      <sec id="article-143336.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are the main radiological modalities for evaluating suspected orbital malignancies. CT of the orbit, including head and paranasal sinuses, is done to see the extent of the lesion, especially as it relates to surrounding bony structures. Expansile or reactive changes to the orbit, as well as gross bony destruction, can both be seen and may hint at the aggressiveness of the underlying tumor.<xref ref-type="bibr" rid="article-143336.r21">[21]</xref>&#x000a0;Multiplanar thin-section MRI of the orbits with intravenous (IV) contrast&#x000a0;is the optimal modality to delineate the soft tissue&#x000a0;extent of the tumor. With such high-resolution imaging, it is possible to determine dural and brain involvement, as well as the extent of sinonasal involvement, by delineating tumor versus inspissated nasal secretions. Features such as diffuse lesions with irregular shapes and borders and involvement of periorbital vessels and nerves indicate malignant lesions rather than benign ones. Diffusion-weighted MRI and dynamic contrast-enhanced MRI studies help differentiate orbital lymphomas from inflammation and other low-grade malignancies. Ultrasonography of the orbit is usually reserved for pulsatile orbital masses like carotid-cavernous fistulas or cystic lesions and has less role in orbital malignancies.<xref ref-type="bibr" rid="article-143336.r22">[22]</xref><xref ref-type="bibr" rid="article-143336.r23">[23]</xref></p>
        <p>After radiological imaging, an orbital biopsy&#x000a0;is typically required to obtain a histologic diagnosis, and an&#x000a0;incisional biopsy is usually sufficient to make a histopathological diagnosis of a suspected malignant orbital mass. Orbital apex, optic nerve, or periocular muscles should be avoided while taking the biopsy. The lesions confined to the orbital bony&#x000a0;walls or the ones that are encroaching less onto surrounding regions like an intracranial cavity or paranasal sinuses can be biopsied via orbital routes like upper eyelid incision or superomedial lid incision with anterior orbitotomy for superiorly and medially based lesions, lateral orbitotomy for orbital apex lesions, and transconjunctival lower anterior orbitotomy for inferiorly based lesions. For orbital malignancies that have extended into the paranasal sinuses or nasal cavity, the endoscopic trans-nasal route is often preferred to obtain a biopsy. Transcranial routes for biopsy are avoided due to the high risk of morbidity. If metastatic cervical lymphadenopathy is present, fine-needle aspiration of the metastasis is often the easiest and safest route to obtain a diagnosis.<xref ref-type="bibr" rid="article-143336.r24">[24]</xref><xref ref-type="bibr" rid="article-143336.r25">[25]</xref></p>
      </sec>
      <sec id="article-143336.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment strategy for orbital malignancy, like any other malignancy, depends upon the extent of the tumor involvement, histopathological type, and tumor stage.</p>
        <p>
<bold>Medical treatment</bold>
</p>
        <p>Of all orbital malignancies, medical treatment (radiation therapy, chemotherapy, and/or immunotherapy) is most commonly used curatively for orbital adnexal lymphomas. For early local tumors, radiotherapy is the primary modality of treatment. Patients with advanced disease and high-grade tumors are treated with chemotherapy followed by local radiation. The standard chemotherapy regimen includes cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP). Rituximab, a monoclonal antibody directed against B-cell specific surface receptor CD20, is used in cases of non-Hodgkins B-cell lymphoma like diffuse large B-cell lymphoma. Surgery has a minimal role in orbital lymphomas.<xref ref-type="bibr" rid="article-143336.r26">[26]</xref><xref ref-type="bibr" rid="article-143336.r27">[27]</xref><xref ref-type="bibr" rid="article-143336.r28">[28]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p>
<bold>Surgical treatment</bold>
</p>
        <p>Surgical treatment is the primary modality of treatment in resectable orbital tumors. The extent of resection depends upon the tumor stage, histology, and primary site and can include local resection, exenteration, or radical exenteration. See StatPearls'&#x000a0;companion reference,&#x000a0;"<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/140265">Lacrimal Gland Malignancies</ext-link>," for more information.<xref ref-type="bibr" rid="article-143336.r29">[29]</xref>&#x000a0;The elective neck dissection and ipsilateral parotidectomy should be discussed in advanced-stage epithelial tumors and are indicated in solid histological subtypes or when there is high-grade malignant degeneration like in carcinoma in pleomorphic adenoma and other high-grade tumors like adenocystic carcinomas. Adjuvant radiotherapy is indicated postsurgery in most of the tumors&#x000a0;for local control after surgery, and brachytherapy for tumors with R1 resection is also a feasible option.<xref ref-type="bibr" rid="article-143336.r26">[26]</xref>&#x000a0;</p>
        <p>See Statpearls' companion references, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/28458">Retinoblastoma</ext-link>" and "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.statpearls.com/point-of-care/26124">Ocular Melanoma</ext-link>," for more information.<xref ref-type="bibr" rid="article-143336.r30">[30]</xref><xref ref-type="bibr" rid="article-143336.r31">[31]</xref></p>
      </sec>
      <sec id="article-143336.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Patients presenting with decreased or double vision, ophthalmoplegia, chemosis, and proptosis should raise concerns for orbital malignancy. However, other conditions should be kept as differentials&#x000a0;because they can mimic orbital malignancy as follows:</p>
        <p>
<bold>Nonspecific orbital inflammation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Also known as orbital pseudotumor, it is a benign, space-occupying, and noninfectious inflammatory condition of the orbit, which may also involve periorbital structures. The exact etiology is unknown, and the histopathology consists of a pleomorphic inflammatory cellular response with a fibrovascular reaction. The commonly encountered presentation is a palpable orbital mass with ptosis and periorbital edema, which may mimic orbital malignancy. Most patients respond well to corticosteroids, but immunomodulatory therapy may be given in selected cases.<xref ref-type="bibr" rid="article-143336.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>IgG-4-related orbital disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This&#x000a0;is a systemic disease that usually presents as lid swelling and proptosis. The proptosis may point towards an orbital mass, but patients typically have minimal signs like mild periorbital pain, unlike in orbital malignancy, in which patients may have pain due to tumor hemorrhage or inflammation. Laboratory analysis shows elevated serum levels of IgG4, IgE, and hypergammaglobulinemia. Patients respond to corticosteroids, but relapse is common. Therefore, azathioprine or rituximab are combined with steroid therapy.<xref ref-type="bibr" rid="article-143336.r33">[33]</xref></p>
          </list-item>
        </list>
        <p>
<bold>ANCA-related vasculitis </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ANCA-related vasculitis like granulomatosis with polyangiitis with or without eosinophilia and sarcoidosis can mimic orbital malignancy due to the involvement of orbital adnexal tissue. The symptoms can vary depending on the extent of tissue involvement. A tissue biopsy is usually required to diagnose and differentiate it from orbital malignancy.</p>
          </list-item>
        </list>
        <p>
<bold>Tolosa-Hunt syndrome</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>This&#x000a0;is idiopathic inflammation in the region of the cavernous sinus and/or superior orbital fissure, resulting in severe unilateral pain and ophthalmoplegia. The absence of a palpable orbital mass or severe proptosis can help differentiate it from an orbital malignancy. The diagnosis is usually made in retrospect after there is a dramatic response of pain and almost complete resolution of ophthalmoplegia to steroids. MRI can show inflammation in the orbital apex, which resolves after administering steroids. Tissue biopsy is rarely required.<xref ref-type="bibr" rid="article-143336.r34">[34]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Langerhans cell histiocytosis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Orbital involvement in Langerhans cell histiocytosis can occur in approximately 20% of the patients and can present with unilateral proptosis similar to orbital malignancy with varying degrees of ophthalmoplegia and visual loss. CT shows typical &#x02018;punched out&#x02019; lytic lesions, and diagnosis is by excisional biopsy. Treatment varies, ranging from observation, curettage, radiation, chemotherapy, or surgical excision, depending upon the extent of involvement.<xref ref-type="bibr" rid="article-143336.r35">[35]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Benign orbital tumors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemangioma is the most common benign intraorbital tumor in adults; dermoid&#x000a0;is the most common benign congenital mass.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Leiomyomas, meningiomas, nerve sheath tumors, neurofibromas, and Warthin tumors have all been described intraorbitally, and all are rare.<xref ref-type="bibr" rid="article-143336.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143336.s10" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgery remains the primary treatment modality for most orbital malignancies that are surgically resectable, and achieving oncologic resection frequently involves sacrifice of the globe. If the tumor has extended into structures that would render it unresectable (brain parenchyma, orbital apex, etc), radiation therapy and chemotherapy have been used in an induction protocol to be followed by surgical resection if the tumor shrinks to where it becomes resectable.<xref ref-type="bibr" rid="article-143336.r37">[37]</xref><xref ref-type="bibr" rid="article-143336.r38">[38]</xref></p>
        <p>Lateral orbitotomy is a safe approach for many extraconal lateral tumors. The extent of lateral orbitotomy depends upon the size, consistency, and nature of the lesion for easy removal and less bony resection. Medial and inferior orbitotomy are combined depending on the location of the tumor. The trans-nasal endoscopic route can be used in conjunction with an open approach for medially located tumors. An open approach for orbital malignancies involving the sinonasal cavity can be achieved by Moure incision along the lateral nasal bone with Diffenbach or Weber and Ferguson extension, depending upon the extension of the tumor. Other open approaches for extensive tumors include bitemporal coronal incision, transmaxillary, transfrontal, midfacial degloving, and facial dismasking approaches.<xref ref-type="bibr" rid="article-143336.r39">[39]</xref><xref ref-type="bibr" rid="article-143336.r40">[40]</xref><xref ref-type="bibr" rid="article-143336.r41">[41]</xref></p>
        <p>Surgical removal of large tumors or orbital contents leads to large defects with potential exposure of the dura or brain. In smaller defects, autografts, xenografts, synthetic materials such as titanium mesh or plates, polyethylene nets, etc, have all been used to successfully reconstruct orbital walls. Suspensionplasty using the temporalis muscle offers the possibility of reducing the size of the resection cavity to facilitate care or ease in fitting a prosthesis. Goals of orbital reconstruction must be established when planning the oncologic resection. Most critical is ensuring complete tumor resection followed by coverage of all critical structures (brain). Following that, orbital reconstruction may be undertaken with the goal of creating a pocket in which to place a prosthesis or may simply involve filling in the resection cavity with tissue. Local and regional flaps such as pericranial and temporoparietal remain workhorses in re-lining reconstructed orbits in preparation for prosthesis. This is often combined with skin grafting. Larger defects, or reconstruction where the goal is simply the obliteration of cavity space, are frequently undertaken with free tissue transfer, with the anterolateral thigh, radial forearm, and latissimus dorsi, among many other flaps routinely used.<xref ref-type="bibr" rid="article-143336.r42">[42]</xref><xref ref-type="bibr" rid="article-143336.r3">[3]</xref><xref ref-type="bibr" rid="article-143336.r43">[43]</xref></p>
      </sec>
      <sec id="article-143336.s11" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Radiation therapy is frequently used in the adjuvant management of advanced orbital malignancy, though it can be used as a primary treatment modality (both curative and palliative) in patients who are not surgical candidates.<xref ref-type="bibr" rid="article-143336.r44">[44]</xref>&#x000a0;Although high-dose external beam radiation therapy is a useful adjuvant treatment for orbital malignancies, it has also been linked to serious toxicity that can affect any area of the orbit, eye, or adnexa. Therefore, volumetric-modulated arc therapy, which is a type of intensity-modulated radiation therapy (IMRT), has been used to mitigate many of these&#x000a0;adverse effects. This therapy reduces exposure to vital structures and allows for the potential of higher doses to the tumor or surgical bed.&#x000a0;</p>
        <p>Over the past&#x000a0;10 years, proton radiation therapy (PRT) has also been utilized increasingly frequently as an option for radiation treatment of orbital malignancies. It results in lower doses&#x000a0;immediately adjacent&#x000a0;to the target volume and allows for total tissue sparing outside the target volume for a given beam. Like PRT, carbon-ion radiotherapy (CIRT) presents a new promising treatment option for tumors resistant to conventional radiotherapy. Radiation-induced optic neuropathy can&#x000a0;cause visual loss or defects in visual fields depending on the area of the optic pathway affected. If the maximum dose to the optic nerve remains &#x0003c;54 to 55 Gy, radiation-induced optic injury is rare, but it is best to keep below 50 Gy if possible and as low as reasonably possible.<xref ref-type="bibr" rid="article-143336.r45">[45]</xref><xref ref-type="bibr" rid="article-143336.r44">[44]</xref></p>
        <p>A report by the American Academy of Ophthalmology evaluating 27 studies comprising 2009 patients demonstrated the efficacy of radiation treatment for ocular lymphoma. The report evaluated cases of extranodal marginal zone lymphoma and mucosa-associated lymphoid tissue and found that the 5-year and 10-year survival rates in patients receiving radiation therapy were 93.8% and 84.9%, respectively. They also concluded that for MALT lymphomas, local control, disease-free survival, and overall survival were good with radiation treatment, and the results of treatment of non-MALT lymphomas using radiotherapy were also good, but they were not as favorable as the treatment results of MALT lymphomas.<xref ref-type="bibr" rid="article-143336.r46">[46]</xref></p>
      </sec>
      <sec id="article-143336.s12" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Currently, most malignant orbital tumors involve the use of radiotherapy in conjunction with surgery. When the surgery involves orbital exenteration, the role of radiotherapy becomes even more important. For instance, orbital exenteration was the gold standard treatment for orbital rhabdomyosarcoma until the 1960s, and it was associated with a 70% mortality if performed alone.<xref ref-type="bibr" rid="article-143336.r47">[47]</xref> However, radiotherapy forms a major part of the treatment of rhabdomyosarcomas currently. The Intergroup Rhabdomyosarcoma Study Group (IRSG) recommendations summarize the current protocols for rhabdomyosarcomas.<xref ref-type="bibr" rid="article-143336.r48">[48]</xref>&#x000a0;With regards to intraocular tumors, the treatment of choroidal melanoma, which is the second most common type of intraocular tumor, was well-studied in the Collaborative Ocular Melanoma Study.<xref ref-type="bibr" rid="article-143336.r49">[49]</xref></p>
      </sec>
      <sec id="article-143336.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>The treatment of advanced local disease&#x000a0;and metastatic disease is often&#x0003e; treated with chemotherapy followed by local radiation. The regimen often follows the CHOP protocol (cyclophosphamide for 375 mg/m<sup>2</sup>, hydroxydaunorubicin for 50mg/m<sup>2</sup>, oncovin for 1.4mg/m<sup>2</sup>, and prednisone for 40mg/m<sup>2</sup>), with rituximab (375mg/m<sup>2</sup>) often given in conjunction to the protocol. Additional treatment regimens include RICE (rituximab for 375 mg/m<sup>2</sup>, ifosfamide for 5000 mg/m<sup>2</sup>, carboplatin optimized for a maximum of 790mg, and etoposide for 100 mg/m<sup>2</sup>). All treatments are given as an IV infusion or IV bolus. The RICE protocol is often used in the salvage treatment of relapsed or refractory Hodgkin and non-Hogkin lymphomas.<xref ref-type="bibr" rid="article-143336.r50">[50]</xref><xref ref-type="bibr" rid="article-143336.r51">[51]</xref></p>
      </sec>
      <sec id="article-143336.s14" sec-type="Staging">
        <title>Staging</title>
        <p>Historically, the most commonly used staging system for ocular adnexal lymphomas was the Ann Arbor Staging system, though the Lugano Staging has largely supplanted this to incorporate PET/CT findings. The TNM classification is the most commonly employed lymphoma staging based on the American Joint Committee on Cancer (AJCC) 8th Edition. However, regardless of staging, the recurrence and disease-free survival are more closely related to tumor histopathology and treatment modality.<xref ref-type="bibr" rid="article-143336.r52">[52]</xref><xref ref-type="bibr" rid="article-143336.r53">[53]</xref><xref ref-type="bibr" rid="article-143336.r54">[54]</xref>&#x000a0;Other orbital malignancies (sarcoma, carcinoma) are staged according to the AJCC 8th edition TNM classification.</p>
        <p>
<bold>Ann Arbor Staging of Lymphoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold>&#x000a0;involvement of a single lymph node region or of a single extralymphatic organ or site</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:</bold>&#x000a0;involvement of&#x000a0;2 or more lymph node regions on the same side of the diaphragm or localized involvement of an extralymphatic organ or site&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:</bold>&#x000a0;involvement of lymph node regions or structures on both sides of the diaphragm</p>
          </list-item>
          <list-item>
            <p><bold>Stage IV:</bold>&#x000a0;diffuse or disseminated involvement of&#x000a0;1 or more extralymphatic organs, or either:&#x000a0;
<list list-type="bullet"><list-item><p>isolated extralymphatic organ involvement without adjacent regional lymph node involvement, but with disease in distant sites</p></list-item><list-item><p>involvement of the liver, bone marrow, pleura, or cerebrospinal fluid</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Additional substaging variables include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>A:&#x000a0;</bold>asymptomatic</p>
          </list-item>
          <list-item>
            <p><bold>B:</bold>&#x000a0;presence of&#x000a0;B symptoms&#x000a0;(including&#x000a0;fever, night sweats,&#x000a0;and&#x000a0;weight loss&#x000a0;of &#x02265;10% of body weight over 6 months)</p>
          </list-item>
          <list-item>
            <p><bold>E</bold>: involvement of a single, extranodal site, contiguous or proximal to a known nodal site (Stages I to III only; additional extranodal involvement is Stage IV)</p>
          </list-item>
          <list-item>
            <p><bold>S</bold>: splenic involvement</p>
          </list-item>
          <list-item>
            <p><bold>X:</bold>&#x000a0;bulky nodal disease: nodal mass larger than one-third of intrathoracic diameter or 10 cm in dimension</p>
          </list-item>
        </list>
        <p><bold>Lugano Staging</bold>&#x000a0;<bold>of Lymphoma</bold></p>
        <p>
<bold>Limited</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold>&#x000a0;1 node or group of adjacent nodes</p>
          </list-item>
          <list-item>
            <p><bold>Stage IE</bold>: single extra-lymphatic site in the absence of nodal involvement&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:</bold>&#x000a0;2 or more nodal groups, <bold>same</bold> side of the diaphragm</p>
          </list-item>
          <list-item>
            <p><bold>Stage IIE</bold>: contiguous extra-lymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm.</p>
          </list-item>
        </list>
        <p>
<bold>Advanced</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage III:</bold>&#x000a0;nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement
<list list-type="bullet"><list-item><p><bold>Stage III(1):</bold>&#x000a0;involvement of the spleen or splenic, hilar, celiac, or portal nodes</p></list-item><list-item><p><bold>Stage III(2):</bold>&#x000a0;&#x000a0;involvement of the para-aortic, iliac, inguinal, or mesenteric nodes&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Stage IV:</bold>&#x000a0;diffuse or disseminated involvement of&#x000a0;1 or more extranodal organs or tissue beyond that designated E, with or without associated lymph node involvement
<list list-type="bullet"><list-item><p>all cases to indicate the absence (<bold>A</bold>) or presence (<bold>B</bold>) of systemic symptoms (fever/night sweats/unexplained weight loss)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item><list-item><p>designation of (<bold>E</bold>) refers to extranodal contiguous extension that can still be encompassed within an irradiation field appropriate for nodal disease of the same anatomic extent (if more extensive than that, label as&#x000a0;<bold>IV</bold>)&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p></list-item><list-item><p>designation of (bulky) if a single nodal mass &#x0003e;10 cm or larger than one-third of the transthoracic diameter</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>AJCC 8th Edition Orbital Adnexal Lymphoma Staging</bold>
</p>
        <p>
<bold>Tumor</bold>
<bold> (T)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>T0</bold>: No evidence of lymphoma</p>
          </list-item>
          <list-item>
            <p><bold>T1</bold>: Lymphoma involving the conjunctiva alone without eyelid or orbital involvement</p>
          </list-item>
          <list-item>
            <p><bold>T2</bold>: Lymphoma with orbital involvement with or without conjunctiva involvement</p>
          </list-item>
          <list-item>
            <p><bold>T3</bold>: Lymphoma with preseptal eyelid involvement with or without orbital involvement and with or without conjunctival involvement</p>
          </list-item>
          <list-item>
            <p><bold>T4</bold>: Orbital adnexal lymphoma and extraorbital lymphoma extending beyond the orbit to adjacent structures, such as bone, maxillofacial sinuses, and brain</p>
          </list-item>
        </list>
        <p>
<bold>Nodes (N)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>N0</bold>: No evidence of lymph node involvement</p>
          </list-item>
          <list-item>
            <p><bold>N1</bold>: Involvement of lymph node region or regions draining the ocular adnexal structures and superior to the mediastinum</p>
          </list-item>
          <list-item>
            <p><bold>N1a</bold>: Involvement of a single lymph node region superior to the mediastinum</p>
          </list-item>
          <list-item>
            <p><bold>N1b</bold>: Involvement of&#x000a0;2 or more lymph node regions superior to the mediastinum</p>
          </list-item>
          <list-item>
            <p><bold>N2</bold>: Involvement of lymph node regions of the mediastinum</p>
          </list-item>
          <list-item>
            <p><bold>N3</bold>: Diffuse or disseminated involvement of peripheral and central lymph node regions</p>
          </list-item>
        </list>
        <p>
<bold>Metastasis (M)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>M0</bold>: No evidence of involvement of other extranodal sites</p>
          </list-item>
          <list-item>
            <p><bold>M1</bold>: Involvement of other extranodal sites</p>
          </list-item>
          <list-item>
            <p><bold>M1a</bold>: Noncontiguous involvement of tissues or organs external to the ocular adnexa (eg, parotid glands, submandibular gland, lung, liver, spleen, kidney, breast)</p>
          </list-item>
          <list-item>
            <p><bold>M1b</bold>: Lymphomatous involvement of the bone marrow</p>
          </list-item>
          <list-item>
            <p><bold>M1c</bold>: Both M1a and M1b involvement</p>
          </list-item>
        </list>
        <p>
<bold>AJCC 8th Edition Orbital Sarcoma Staging</bold>
</p>
        <p>
<bold>Tumor (T)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>TX:</bold>&#x000a0;primary tumor cannot be assessed</p>
          </list-item>
          <list-item>
            <p><bold>T0:</bold>&#x000a0;no evidence of primary tumor</p>
          </list-item>
          <list-item>
            <p><bold>T1:</bold>&#x000a0;tumor &#x02264;15 mm in greatest dimension</p>
          </list-item>
          <list-item>
            <p><bold>T2:</bold>&#x000a0;tumor &#x0003e;15 mm in greatest dimension without invasion of globe or bony wall</p>
          </list-item>
          <list-item>
            <p><bold>T3:</bold>&#x000a0;tumor of any size with invasion of orbital tissues or bony walls</p>
          </list-item>
          <list-item>
            <p><bold>T4:</bold>&#x000a0;tumor invasion of globe or periorbital structure, such as eyelids, temporal fossa, nasal cavity and paranasal sinuses, or central nervous system</p>
          </list-item>
        </list>
        <p>
<bold>Nodes (N)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NX:</bold>&#x000a0;regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p><bold>N0:</bold>&#x000a0;no regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p><bold>N1:</bold>&#x000a0;regional lymph node metastasis</p>
          </list-item>
        </list>
        <p>
<bold>Metastasis (M)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>M0:</bold>&#x000a0;no distant metastasis</p>
          </list-item>
          <list-item>
            <p><bold>M1:</bold>&#x000a0;distant metastasis</p>
          </list-item>
        </list>
        <p>
<bold>AJCC 8th Edition Cutaneous Carcinoma of the Head and Neck Staging</bold>
</p>
        <p>
<bold>Tumor (T)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>TX</bold>&#x000a0;&#x000a0; Primary tumor cannot be assessed</p>
          </list-item>
          <list-item>
            <p><bold>Tis</bold>&#x000a0;&#x000a0; Carcinoma in situ</p>
          </list-item>
          <list-item>
            <p><bold>T1</bold>&#x000a0;&#x000a0; Tumor &#x02264;2 cm in greatest dimension</p>
          </list-item>
          <list-item>
            <p><bold>T2</bold>&#x000a0;&#x000a0; Tumor &#x0003e; 2 cm but &#x02264;4 cm in greatest dimension</p>
          </list-item>
          <list-item>
            <p><bold>T3</bold>&#x000a0;&#x000a0; Tumor &#x0003e; 4 cm in maximum dimension or minor bone erosion or perineural invasion or deep invasion*</p>
          </list-item>
          <list-item>
            <p><bold>T4</bold>&#x000a0; &#x000a0;Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion</p>
          </list-item>
          <list-item>
            <p><bold>T4a</bold>&#x000a0;&#x000a0; Tumor with gross cortical bone/marrow invasion</p>
          </list-item>
          <list-item>
            <p><bold>T4b</bold>&#x000a0;&#x000a0; Tumor with&#x000a0;skull base invasion and/or skull base foramen involvement</p>
          </list-item>
        </list>
        <p>* Deep invasion is defined as invasion beyond the subcutaneous fat or &#x0003e;6 cm (as measured from the granular layer of adjacent normal epidermis to the base of the tumor); perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring &#x02265;0.1 mm in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression.</p>
        <p><bold>Nodes (N)</bold>&#x000a0;</p>
        <p>
<italic toggle="yes">Clinical N (cN)</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NX</bold>&#x000a0;&#x000a0; Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p><bold>N0</bold>&#x000a0;&#x000a0; No regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p><bold>N1</bold>&#x000a0;&#x000a0; Metastasis in a single ipsilateral lymph node &#x02264;3 cm in greatest dimension and no extranodal extension (ENE [-])</p>
          </list-item>
          <list-item>
            <p><bold>N2</bold>&#x000a0; &#x000a0; Metastasis in a single ipsilateral lymph node &#x0003e;3 cm but not more than 6 cm in greatest dimension and ENE (-); or&#x000a0;metastases&#x000a0;in multiple ipsilateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-); or&#x000a0;in bilateral or contralateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2a</bold>&#x000a0;&#x000a0; Metastasis in a single ipsilateral lymph node &#x0003e;3 cm but not more than 6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2b</bold>&#x000a0;&#x000a0; Metastasis in multiple ipsilateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2c</bold>&#x000a0;&#x000a0; Metastasis in bilateral or contralateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N3</bold>&#x000a0;&#x000a0; Metastasis in a lymph node &#x0003e;6 cm in greatest dimension and ENE (-); or metastasis in any node(s) with clinically overt ENE (+)</p>
          </list-item>
          <list-item>
            <p><bold>N3a</bold>&#x000a0;&#x000a0; Metastasis in a lymph node &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N3b&#x000a0;</bold>&#x000a0; Metastasis in any node(s) with clinically overt ENE (+)&#x000a0;</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">Pathological N (pN)</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NX</bold>&#x000a0;&#x000a0; Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p><bold>N0</bold>&#x000a0;&#x000a0; No regional lymph node metastasis</p>
          </list-item>
          <list-item>
            <p><bold>N1</bold>&#x000a0; &#x000a0;Metastasis in a single ipsilateral lymph node &#x02264;3 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2</bold>&#x000a0;&#x000a0; Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (+); or&#x000a0;a single ipsilateral lymph node &#x0003e;3 cm but not more than 6 cm in greatest dimension and ENE (-); or&#x000a0;metastases&#x000a0;in multiple ipsilateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-); or&#x000a0;in bilateral or contralateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2a</bold>&#x000a0;&#x000a0; Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (+); or&#x000a0;a single ipsilateral lymph node &#x0003e;3 cm but not more than 6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2b</bold>&#x000a0;&#x000a0; Metastasis in multiple ipsilateral lymph nodes, none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N2c</bold>&#x000a0;&#x000a0; Metastasis in bilateral or contralateral lymph node(s), none &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N3</bold>&#x000a0;&#x000a0; Metastasis in a lymph node &#x0003e;6 cm in greatest dimension and ENE (-); or&#x000a0;in a single ipsilateral node &#x0003e; 3 cm in greatest dimension and ENE (+); or&#x000a0;multiple ipsilateral, contralateral, or bilateral nodes, any with&#x000a0;ENE (+); or&#x000a0;a single contralateral node of any size and ENE (+)</p>
          </list-item>
          <list-item>
            <p><bold>N3a</bold>&#x000a0;&#x000a0; Metastasis in a lymph node &#x0003e;6 cm in greatest dimension and ENE (-)</p>
          </list-item>
          <list-item>
            <p><bold>N3b</bold>&#x000a0;&#x000a0; Metastasis in a single ipsilateral node &#x0003e;3 cm in greatest dimension and ENE (+); or&#x000a0;multiple ipsilateral, contralateral, or bilateral nodes, any with&#x000a0;ENE (+); or&#x000a0;a single contralateral node of any size and ENE (+)</p>
          </list-item>
        </list>
        <p>
<bold>Metastasis (M)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>cM0</bold>&#x000a0; &#x000a0;No distant metastasis</p>
          </list-item>
          <list-item>
            <p><bold>cM1</bold>&#x000a0;&#x000a0; Distant metastasis</p>
          </list-item>
          <list-item>
            <p><bold>pM1</bold>&#x000a0;&#x000a0; Distant metastasis, microscopically confirmed</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143336.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of orbital malignant tumors depends upon the histological type and stage. For orbital adnexal lymphomas (OALs), Rath et al proposed a scoring system for prognostication based on their laterality and node/metastatic status. They divided the patients into&#x000a0;3 groups: Group 1 with unilateral OALs with no nodes or metastasis, Group 2 with either bilateral or positive nodes/metastasis, and Group 3 with bilateral OALs with positive nodes/metastasis. The 10-year progression-free survival was 75%, 50%, and&#x000a0;0 in these groups, respectively.<xref ref-type="bibr" rid="article-143336.r54">[54]</xref>&#x000a0;</p>
        <p>Overall, 5-year survival for orbital rhabdomyosarcoma with combined surgical and medical treatment is &#x0003e;90%.<xref ref-type="bibr" rid="article-143336.r55">[55]</xref>&#x000a0;The prognosis of malignant orbital melanomas remains poor.<xref ref-type="bibr" rid="article-143336.r56">[56]</xref></p>
      </sec>
      <sec id="article-143336.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Understanding the potential complications associated with malignant orbital tumors is essential for clinicians managing these complex conditions, as they significantly impact patient outcomes and treatment strategies. Complications include the following:</p>
        <p><bold>Tumor-related complications:&#x000a0;</bold>Complete ophthalmoplegia, visual loss, superadded infection leading to periorbital cellulitis, extension into adjoining areas like the nose and paranasal sinuses leading to unilateral nasal obstruction or recurrent epistaxis, or extension to the intracranial cavity leading to meningismus.</p>
        <p><bold>Surgery-related complications:&#x000a0;</bold>Patients with orbital malignancies suitable for surgery usually undergo wide local excision or orbital exenteration, leading to a non-aesthetic orbital cavity requiring reconstruction, which further leads to flap-related complications. Intraoperative complications include injury to the skull base or dura leading to a cerebrospinal fluid leak in addition to the usual risk of bleeding, compressive hematoma, vision loss, injury to the lacrimal duct leading to epiphora, cosmetic deformities, enophthalmos, and exposure keratopathy in the case of globe preservation surgeries.</p>
        <p><bold>Radiotherapy-related complications:&#x000a0;</bold>Radiotherapy-related complications include damage to the radiosensitive lens, lacrimal gland, and retina located near or within the target volume.</p>
      </sec>
      <sec id="article-143336.s17" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative rehabilitation for malignant orbital tumors typically involves a multidisciplinary approach aimed at restoring function, addressing complications, and maximizing the quality of life for the patient. The specific rehabilitation plan may vary depending on factors such as the type and extent of the tumor, the surgical procedure performed, and individual patient needs. However, some common aspects of postoperative rehabilitation for malignant orbital tumors are as follows:</p>
        <p><bold>Wound care:&#x000a0;</bold>Proper wound care is crucial to prevent infection and promote healing after any surgery. This may involve regular cleaning of the surgical site, application of topical medications, and monitoring for any signs of infection.</p>
        <p><bold>Prosthetic rehabilitation:&#x000a0;</bold>An ocular prosthesis can improve overall cosmesis and self-image in patients who have undergone enucleation or exenteration. The remaining orbit may require surgical preparation to optimize the fit of a prosthetic. Of course, patients may always elect to wear patches or opaque-lens glasses if they would prefer.</p>
        <p><bold>Pain management:&#x000a0;</bold>Patients may experience pain and discomfort following surgery, which can be managed with medications prescribed by the healthcare team. Nonpharmacological pain management techniques such as relaxation exercises and ice packs may also be recommended.</p>
        <p><bold>Eye care:&#x000a0;</bold>Patients who have undergone wide local excision or orbital exenteration may need rehabilitation in the form of revision oculoplastic surgery and visual aids. In cases where the tumor has resulted in significant disfigurement or loss of an eye, prosthetic rehabilitation with a custom ocular prosthesis may be considered to restore appearance and self-esteem.</p>
        <p><bold>Speech and swallow therapy:&#x000a0;</bold>Therapy is important in patients who have undergone surgery for secondary orbital malignancies originating in the sinonasal cavity, as surgical resection of this region can affect nasality in speech, palatal movement, smell, and taste. A consultation with a dedicated speech and language therapy team is needed.</p>
        <p><bold>Psychological support:&#x000a0;</bold>As with any malignancy, coping with a malignant orbital tumor and its treatment can be emotionally challenging for patients. Psychological support from counselors, psychologists, or support groups can help patients and their families cope with anxiety, depression, and other emotional issues arising out of the overwhelming treatment for the malignancy.</p>
        <p><bold>Follow-up care:&#x000a0;</bold>Regular follow-up appointments with the interprofessional healthcare team are essential to monitoring recovery, detecting any complications early, and adjusting the rehabilitation plan as needed.</p>
      </sec>
      <sec id="article-143336.s18" sec-type="Consultations">
        <title>Consultations</title>
        <p>Patients diagnosed with any orbital malignancy&#x000a0;are best managed by a multidisciplinary team that includes surgeons (which can include ophthalmologists, head-neck surgeons, neurosurgeons, maxillofacial surgeons, craniofacial surgeons, or plastic surgeons), medical and radiation oncologists, radiologists, social workers, psychologists or psychiatrists, and a care coordinator.</p>
      </sec>
      <sec id="article-143336.s19" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and prevention strategies for malignant orbital tumors primarily focus on early detection, prompt treatment of predisposing conditions, and minimizing exposure to known risk factors. Regular eye exams, especially for individuals with a family history of orbital tumors or predisposing genetic conditions, can aid in early detection.&#x000a0;Patients&#x000a0;should not delay presenting to their primary care physician eye symptoms, which include vision changes (change in acuity, diplopia), eye movement, persistent eye pain, or gross asymmetry in the appearance of the eye. Such signs and symptoms may suggest underlying orbital malignancy and an expedited workup via imaging and specialist referral is paramount. Red flag signs such as proptosis, ophthalmoplegia, unilateral headaches, and unilateral nasal obstruction or recurrent epistaxis should never be ignored as these can be a deterrent against impending complications.</p>
        <p>Additionally, promoting healthy lifestyle choices, such as avoiding tobacco use and excessive sun exposure, may reduce the risk of certain orbital malignancies. Clinicians should emphasize the importance of protective eyewear in high-risk occupations or activities to prevent traumatic injuries that could predispose individuals to orbital tumors. Education campaigns targeting both healthcare professionals and the general public can raise awareness about the signs and symptoms of orbital tumors, encouraging timely medical evaluation and intervention. Comprehensive preventive measures and proactive health management can minimize the incidence and impact of malignant orbital tumors.</p>
      </sec>
      <sec id="article-143336.s20" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Diagnosing orbital malignancy in the early stages is important to formulate treatment plans and avoid disease-related complications. The radiology can point towards a malignant orbital mass, but a diagnostic biopsy is the gold standard and must be obtained before commencing any treatment. Depending upon the extent of the tumor, it can either be done externally or by less invasive routes like endoscopically by the trans-nasal route. Acute inflammation occurring in the tumor bed can be managed with intravenous steroids, but this must be differentiated from other differential diagnoses, such as IgG4-related orbital disease or Tolosa-Hunt syndrome, which presents with similar symptoms and also responds to steroids.<xref ref-type="bibr" rid="article-143336.r33">[33]</xref><xref ref-type="bibr" rid="article-143336.r34">[34]</xref></p>
        <p>Diagnosing metastatic orbital lesions needs a high degree of suspicion as the orbit is an unusual site for metastasis. In a study by Eldesouky et al, 24.3% of the patients did not have a history of cancer, and an orbital lesion was the first manifestation of the disease.<xref ref-type="bibr" rid="article-143336.r57">[57]</xref>&#x000a0;A comprehensive multidisciplinary approach involving oncologists is required in such patients.</p>
      </sec>
      <sec id="article-143336.s21" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the comprehensive management of malignant orbital tumors, an interprofessional healthcare team comprising physicians, advanced care practitioners, nurses, pharmacists, and other health professionals plays a crucial role in delivering patient-centered care, optimizing outcomes, ensuring patient safety, and enhancing team performance.&#x000a0;Healthcare professionals must possess a diverse skill set to effectively manage malignant orbital tumors. This includes proficiency in diagnostic techniques such as imaging interpretation and biopsy procedures, as well as surgical skills for tumor resection. Continuous training and skill development are essential to stay abreast of advancements in diagnostic modalities and treatment options.</p>
        <p>Malignant orbital tumors should be classified as primary, secondary, or metastatic early on to streamline the healthcare team who will be leading the management.&#x000a0;A strategic approach to managing malignant orbital tumors involves developing individualized treatment plans based on the patient's specific tumor characteristics, overall health status, and personal preferences. This requires careful consideration of various treatment modalities, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with the goal of achieving optimal outcomes while minimizing treatment-related morbidity. Surgical interventions like orbital exenteration can have a toll on a patient's mental health, and therefore, a detailed discussion with the patient and family members is needed with a focus on explaining the need for the procedure, associated risks, and consequences of not having the procedure. For those undergoing chemoradiation therapy, either as a primary modality or as adjuvant therapy after surgery, prognosis and risk of recurrence should be part of the discussion.</p>
        <p>Care coordination ensures seamless transitions between different phases of care and across healthcare settings. This involves liaising with various healthcare professionals, coordinating appointments and procedures, facilitating access to supportive services such as physical therapy and palliative care, and engaging patients and their families as active partners in the care process.&#x000a0;The management of malignant orbital masses requires the involvement of multiple medical and surgical teams to provide patients with the best treatment options.&#x000a0;Together, they enhance patient-centered care, improve outcomes, promote patient safety, and optimize team performance.</p>
      </sec>
      <sec id="article-143336.s22">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143336&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143336">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/malignant-orbital-tumors/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=143336">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143336/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143336">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-143336.s23">
        <title>References</title>
        <ref id="article-143336.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turvey</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Orbital anatomy for the surgeon.</article-title>
            <source>Oral Maxillofac Surg Clin North Am</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-36</page-range>
            <pub-id pub-id-type="pmid">23107426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papanagiotou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grunwald</surname>
                <given-names>IQ</given-names>
              </name>
              <name>
                <surname>Politi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reith</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>[Orbital tumors].</article-title>
            <source>Radiologe</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>48</volume>
            <issue>12</issue>
            <fpage>1133</fpage>
            <page-range>1133-42</page-range>
            <pub-id pub-id-type="pmid">19002664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertelmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erb</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Malignant neoplasms of the orbit].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2012</year>
            <month>May</month>
            <volume>229</volume>
            <issue>5</issue>
            <fpage>e15</fpage>
            <page-range>e15-29; quiz 30-1</page-range>
            <pub-id pub-id-type="pmid">22576359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ducasse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merol</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bonnet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Litr&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Larr&#x000e9;</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>[Adult orbital tumors].</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-99</page-range>
            <pub-id pub-id-type="pmid">27017475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mombaerts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ramberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of orbital mass lesions: clinical, radiological, and pathological recommendations.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2019</year>
            <season>Nov-Dec</season>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>741</fpage>
            <page-range>741-756</page-range>
            <pub-id pub-id-type="pmid">31276737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laplant</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cockerham</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Primary Malignant Orbital Tumors.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">33777620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castillo</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pediatric tumors of the eye and orbit.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>149</fpage>
            <page-range>149-72</page-range>
            <pub-id pub-id-type="pmid">12713110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmisciano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wahood</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bin Alamer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Scalia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>AMG</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Umana</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Cohen-Gadol</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>El Ahmadieh</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Haider</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Orbital Metastases: A Systematic Review of Clinical Characteristics, Management Strategies, and Treatment Outcomes.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Dec</month>
            <day>24</day>
            <volume>14</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35008259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonavolont&#x000e0;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Strianese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Comune</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tranfa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Uccello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iuliano</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>An analysis of 2,480 space-occupying lesions of the orbit from 1976 to 2011.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>2013</year>
            <season>Mar-Apr</season>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-86</page-range>
            <pub-id pub-id-type="pmid">23470516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honavar</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Manjandavida</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Recent Advances in Orbital Tumors--A Review of Publications from 2014-2016.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-158</page-range>
            <pub-id pub-id-type="pmid">28399335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tailor</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dalley</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Keene</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Anzai</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Orbital neoplasms in adults: clinical, radiologic, and pathologic review.</article-title>
            <source>Radiographics</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>1739</fpage>
            <page-range>1739-58</page-range>
            <pub-id pub-id-type="pmid">24108560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rasmussen</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>91 Thesis 5</volume>
            <fpage>1</fpage>
            <page-range>1-27</page-range>
            <pub-id pub-id-type="pmid">24041159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kunesh</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Thuro</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Malignant peripheral nerve sheath tumor of the orbit: a case report and review of the literature.</article-title>
            <source>Orbit</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>642</fpage>
            <page-range>642-646</page-range>
            <pub-id pub-id-type="pmid">33926355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caruntu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moraru</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lupu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ciubotaru</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dumitrescu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eftimie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hertzog</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zurac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Caruntu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Voinea</surname>
                <given-names>OC</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>May</month>
            <day>27</day>
            <volume>10</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34071843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niculet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Craescu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rebegea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bobeica</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nastase</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lupasteanu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Chioncel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Anghel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lungu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tatu</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Basal cell carcinoma: Comprehensive clinical and histopathological aspects, novel imaging tools and therapeutic approaches (Review).</article-title>
            <source>Exp Ther Med</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">34917186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Topilow</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>AQ</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Alabiad</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Etiologies of Proptosis: A review.</article-title>
            <source>Intern Med Rev (Wash D C)</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">32382689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maddileti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaliki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mariappan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Generation of an induced pluripotent stem cell line (LVPEIi002-A) with heterozygous RB1 mutation using peri-orbital fat derived mesenchymal cells of a patient with inherited retinoblastoma.</article-title>
            <source>Stem Cell Res</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>76</volume>
            <fpage>103329</fpage>
            <pub-id pub-id-type="pmid">38335663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neems</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Echalier</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Subramanian</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Orbital Tumors and Inflammatory Disorders: Diagnosis and Management.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2018</year>
            <season>Spring</season>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-195</page-range>
            <pub-id pub-id-type="pmid">29517650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poloschek</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lagr&#x000e8;ze</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Ridder</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hader</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Clinical and neuroradiological diagnostics of orbital tumors].</article-title>
            <source>Ophthalmologe</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>510</fpage>
            <page-range>510-8</page-range>
            <pub-id pub-id-type="pmid">21695605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groe</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Orbital diagnosis.</article-title>
            <source>Head Neck Surg</source>
            <year>1979</year>
            <season>Sep-Oct</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-24</page-range>
            <pub-id pub-id-type="pmid">400657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maripudi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sarcoid-like reaction of the orbit in diffuse large B-cell lymphoma.</article-title>
            <source>Orbit</source>
            <year>2024</year>
            <month>Mar</month>
            <day>05</day>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">38441528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weisman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kikkawa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moe</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Osguthorpe</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Orbital tumors.</article-title>
            <source>Otolaryngol Clin North Am</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1157</fpage>
            <page-range>1157-74, ix-x</page-range>
            <pub-id pub-id-type="pmid">11728939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Orbital malignant lesions in adults: multiparametric MR imaging.</article-title>
            <source>Jpn J Radiol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>454</fpage>
            <page-range>454-462</page-range>
            <pub-id pub-id-type="pmid">28550356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abussuud</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paluzzi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Surgical Approaches to the Orbit: A Neurosurgical Perspective.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-408</page-range>
            <pub-id pub-id-type="pmid">33209566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamed-Azzam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verity</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Lateral canthotomy orbitotomy: a rapid approach to the orbit.</article-title>
            <source>Eye (Lond)</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>333</fpage>
            <page-range>333-337</page-range>
            <pub-id pub-id-type="pmid">28862259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kisser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Heichel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glien</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Rare Diseases of the Orbit.</article-title>
            <source>Laryngorhinootologie</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>100</volume>
            <issue>S 01</issue>
            <fpage>S1</fpage>
            <page-range>S1-S79</page-range>
            <pub-id pub-id-type="pmid">34352903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yadav</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Orbital lymphoma: role of radiation.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2009</year>
            <season>Mar-Apr</season>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-7</page-range>
            <pub-id pub-id-type="pmid">19237780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tuncer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tany&#x00131;ld&#x00131;z</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Basaran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buyukbabani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.</article-title>
            <source>Curr Eye Res</source>
            <year>2015</year>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>780</fpage>
            <page-range>780-5</page-range>
            <pub-id pub-id-type="pmid">25247376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mueller</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Czyz</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <chapter-title>Lacrimal Gland Malignancies</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">35201715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ishaq</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Retinoblastoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">31424860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Ocular Melanoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">31869111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ronquillo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <chapter-title>Nonspecific Orbital Inflammation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31869057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moritani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Orbital IgG4-Related Disease: Clinical Features and Diagnosis.</article-title>
            <source>ISRN Rheumatol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>412896</fpage>
            <pub-id pub-id-type="pmid">22778989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuliati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajamani</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Tolosa-Hunt Syndrome.</article-title>
            <source>Neurohospitalist</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-105</page-range>
            <pub-id pub-id-type="pmid">29623162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herwig</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wojno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Grossniklaus</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2013</year>
            <season>Jul-Aug</season>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>330</fpage>
            <page-range>330-40</page-range>
            <pub-id pub-id-type="pmid">23246282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purohit</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Ailianou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Poletti</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Platon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delattre</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rager</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Burkhardt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Orbital tumours and tumour-like lesions: exploring the armamentarium of multiparametric imaging.</article-title>
            <source>Insights Imaging</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-68</page-range>
            <pub-id pub-id-type="pmid">26518678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Multimodal Treatment With Orbital Organ Preservation in Adult Patients With Locally Advanced Small-Round-Cell Malignancy of the Nasal Cavity and Paranasal Sinus.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>650385</fpage>
            <pub-id pub-id-type="pmid">33869053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lilly</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geltzeiler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Induction Chemotherapy for Orbit Preservation in Sinonasal Squamous Cell Carcinoma.</article-title>
            <source>J Neurol Surg Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>e36</fpage>
            <page-range>e36-e37</page-range>
            <pub-id pub-id-type="pmid">34603932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Daglioglu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Akdemir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalgic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uckun</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Atasoy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Belen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Lateral orbitotomy approach to orbital tumors: report of 10 cases.</article-title>
            <source>Turk Neurosurg</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">20401844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bewley</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Farwell</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Management of orbital tumours.</article-title>
            <source>Curr Opin Otolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-15</page-range>
            <pub-id pub-id-type="pmid">26101874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Use of the facial dismasking flap approach for surgical treatment of a multifocal craniofacial abscess.</article-title>
            <source>Arch Plast Surg</source>
            <year>2018</year>
            <month>May</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-274</page-range>
            <pub-id pub-id-type="pmid">29788681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jian</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Surgical Management of Complex Skull Base Tumor Using Preoperative Multimodal Image Fusion Technology.</article-title>
            <source>J Craniofac Surg</source>
            <year>2024</year>
            <month>Mar</month>
            <day>27</day>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>853</fpage>
            <page-range>853-9</page-range>
            <pub-id pub-id-type="pmid">38534161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudecki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolany</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Likus</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Markowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kolano-Burian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00141;uczak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zorychta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawecki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x00141;os</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Orbital reconstruction - applied materials, therapeutic agents and clinical problems of restoration of defects.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2021</year>
            <month>Feb</month>
            <day>05</day>
            <volume>892</volume>
            <fpage>173766</fpage>
            <pub-id pub-id-type="pmid">33249074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ioakeim-Ioannidou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Evolution of Care of Orbital Tumors with Radiation Therapy.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>4</issue>
            <fpage>480</fpage>
            <page-range>480-496</page-range>
            <pub-id pub-id-type="pmid">33072488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Charlson</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Kolseth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kossler</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Ocular, Orbital, and Adnexal Toxicity With High-dose Volumetric Modulated Arc Radiation Therapy for Orbital Malignancies.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <string-date>2022 Mar-Apr 01</string-date>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>132</fpage>
            <page-range>132-137</page-range>
            <pub-id pub-id-type="pmid">34284423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yen</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bilyk</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wladis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mawn</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Treatments for Ocular Adnexal Lymphoma: A Report by the American Academy of Ophthalmology.</article-title>
            <source>Ophthalmology</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-136</page-range>
            <pub-id pub-id-type="pmid">28712656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shields</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyosarcoma: review for the ophthalmologist.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2003</year>
            <season>Jan-Feb</season>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-57</page-range>
            <pub-id pub-id-type="pmid">12559326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raney</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Andrassy</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Qualman</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wharam</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Wiener</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Crist</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.</article-title>
            <source>Sarcoma</source>
            <year>2001</year>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-15</page-range>
            <pub-id pub-id-type="pmid">18521303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hawkins</surname>
                <given-names>BS</given-names>
              </name>
              <collab>Collaborative Ocular Melanoma Study Group</collab>
            </person-group>
            <article-title>The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>138</volume>
            <issue>6</issue>
            <fpage>936</fpage>
            <page-range>936-51</page-range>
            <pub-id pub-id-type="pmid">15629284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lepage</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Briere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Den Neste</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lederlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gisselbrecht</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Jan</month>
            <day>24</day>
            <volume>346</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-42</page-range>
            <pub-id pub-id-type="pmid">11807147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kewalramani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Nimer</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Portlock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Noy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Filippa</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Teruya-Feldstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gencarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>May</month>
            <day>15</day>
            <volume>103</volume>
            <issue>10</issue>
            <fpage>3684</fpage>
            <page-range>3684-8</page-range>
            <pub-id pub-id-type="pmid">14739217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graue</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Finger</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Della Rocca</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Della Rocca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lelli</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Milman</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2013</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-55</page-range>
            <pub-id pub-id-type="pmid">23397158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Edge</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Brookland</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>67</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-99</page-range>
            <pub-id pub-id-type="pmid">28094848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dolman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rootman</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of American Joint Committee on Cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma.</article-title>
            <source>Orbit</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-8</page-range>
            <pub-id pub-id-type="pmid">24180616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Honavar</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>An update on ocular adnexal lymphoma.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2016</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-72</page-range>
            <pub-id pub-id-type="pmid">26972223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reichegger</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ricci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corradi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gandolfi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sesenna</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Surgical management of orbital malignant melanoma: our experience and a report of three cases].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>224</volume>
            <issue>10</issue>
            <fpage>794</fpage>
            <page-range>794-8</page-range>
            <pub-id pub-id-type="pmid">17952825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143336.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eldesouky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elbakary</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Clinical and imaging characteristics of orbital metastatic lesions among Egyptian patients.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>1683</fpage>
            <page-range>1683-7</page-range>
            <pub-id pub-id-type="pmid">26392748</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
